Red wine compound increases anti-tumor effect of rapamycin

Feb 14, 2011

Cleveland – Researchers from Cleveland Clinic's Lerner Research Institute have discovered that resveratrol – a compound found in red wine – when combined with rapamycin can have a tumor-suppressing effect on breast cancer cells that are resistant to rapamycin alone.

The research – recently published in Cancer Letters – also indicates that the PTEN tumor-suppressing gene contributes to resveratrol's anti-tumor effects in this treatment combination.

Charis Eng, MD, Ph.D., Chair of the Genomic Medicine Institute of Cleveland Clinic's Lerner Research Institute, led her team to study the effect of combining resveratrol, a chemopreventive drug found in many natural compounds, with rapamycin on cells. The research demonstrates an additive effect between these two drugs on breast cancer cell signaling and growth.

"Rapamycin has been used in clinical trials as a cancer treatment. Unfortunately, after a while, the develop resistance to rapamycin," Eng said. "Our findings show that resveratrol seems to mitigate rapamycin-induced drug resistance in breast cancers, at least in the laboratory. If these observations hold true in the clinic setting, then enjoying a glass of red wine or eating a bowl of boiled peanuts – which has a higher resveratrol content than red wine – before rapamycin treatment for cancer might be a prudent approach."

Rapamycin, an immunosuppressant drug used to prevent rejection in organ transplantation, has been considered for the use of anti-tumor activity against breast cancer. Resveratrol is a type of polyphenol that is found in the skin of red grapes and is a constituent of , and has been considered for multiple uses regarding cellular therapies.

Despite the potential for tumor suppression, rapamycin's efficacy with respect to growth inhibition differs markedly among various breast cancer cell lines. The effect of resveratrol and rapamycin, alone and in combination, on cell growth of three human breast cancer cell lines was assessed. Rapamycin, resveratrol, and combinations of these agents inhibited cell growth in a dose-dependent manner. In all three cell lines tested, the presence of low concentrations of resveratrol and was sufficient to induce 50 percent growth inhibition. Although relatively early, these observations may suggest resveratrol as a powerful integrative medicine adjunct to traditional chemotherapy.

Explore further: Target growth-driving cells within tumors, not fastest-proliferating cells

Provided by Lerner Research Institute

4.5 /5 (8 votes)

Related Stories

An Achilles heel in cancer cells

Dec 08, 2008

A protein that shields tumor cells from cell death and exerts resistance to chemotherapy has an Achilles heel, a vulnerability that can be exploited to target and kill the very tumor cells it usually protects, researchers ...

Recommended for you

Same cancer, different time zone

13 hours ago

Just as no two people possess the same genetic makeup, a recent study has shown that no two single tumor cells in breast cancer patients have an identical genome.

Brazilian researchers identify RNA that regulates cell death

17 hours ago

Researchers from the University of São Paulo (USP) have identified an RNA known as INXS that, although containing no instructions for the production of a protein, modulates the action of an important gene in the process ...

User comments : 0